Tscan Therapeutics, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.

TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer, with additional target discovery work in autoimmune disorders. The TCRX news page on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how TScan’s programs evolve over time.

News coverage for TCRX often centers on the company’s hematologic malignancies program, particularly TSC-101 and the ALLOHA™ Phase 1 heme trial in patients with AML, ALL, or MDS undergoing allogeneic hematopoietic cell transplantation. Updates include clinical data readouts, such as relapse-free survival and overall survival observations, safety findings, and details on manufacturing process changes for TSC-101. Regulatory milestones, including alignment with the U.S. Food and Drug Administration on a pivotal trial design that mirrors the ALLOHA study, are also key topics in TScan’s press releases.

Investors and observers can also expect TCRX news about the PLEXI-T™ Phase 1 solid tumor trial, the company’s ImmunoBank of therapeutic TCRs, and its strategic decisions to prioritize the heme program while pausing further enrollment in the solid tumor trial. Additional updates highlight the development of in vivo-engineered TCR-T approaches for solid tumors, presentations at scientific meetings such as ASH, ASGCT, and ACR, and TargetScan-based discoveries in T cell-mediated autoimmune disorders.

Financial results, corporate strategy updates, workforce changes, and participation in investor conferences are reported through earnings releases and Form 8-K filings. By reviewing the TCRX news feed, readers gain context on TScan’s clinical progress, regulatory interactions, operational priorities, and research activities across oncology and autoimmunity.